As new insulin formulations become available, it is important to understand the preferences of people living with type 2 diabetes (T2D) and healthcare providers (HCPs) compared to existing insulins. This study hypothesized that once-weekly (OW) basal insulin is the preferred insulin of choice by HCPs for their patients due to providing a higher level of comfort in prescribing for patients, and it is also preferred by patients by reducing the treatment burden for their initiation of insulin therapy. Across all cohort types, both adults with T2D and HCPs demonstrated a strong preference for OW basal insulin when compared to existing basal insulin. Insulin delivery method and insulin type were considered the most important attributes for both stakeholder groups.